TriCelX wins FDA clearance for ALS XytriX trial

TriCelX said the FDA cleared its third 2026 IND, allowing a Phase 1/2 ALS study of XytriX to begin in people recently diagnosed with the disease. The trial will test intravenous and first-time needle-free intranasal delivery as the company extends the same platform it is already using in knee osteoarthritis and CTE.

Why it matters: - TriCelX is moving XytriX into ALS, a disease with limited treatment options and rapid progression. - The study tests whether the same platform used in the company’s CTE and knee programs can help slow functional decline in ALS. - The trial also introduces a first-in-program intranasal delivery route that could expand how XytriX is administered.

What happened: - The U.S. Food and Drug Administration’s Center for Biologics Evaluation and Research notified TriCelX that its Phase 1/2 ALS study may proceed under IND 33245. - This is TriCelX’s third cleared IND in 2026, after knee osteoarthritis in April and chronic traumatic encephalopathy in June. - All three programs use XytriX made from the same cell banks to the same release standards. - The ALS study is designed for adults who were diagnosed early, within 18 months of first symptoms and 12 months of diagnosis. - Dr. Abdul Baker, TriCelX’s chief medical and scientific officer, is principal investigator and will run the trial at the Baylor Scott & White Sports Therapy & Research Center in Frisco, Texas.

The details: - Protocol TCX-ALS-001 is an open-label Phase 1/2 study of 20 adults with ALS. - Participants are assigned to four arms of five: intravenous XytriX, two intranasal dose levels, or a combined intranasal-plus-intravenous arm. - Each participant receives three monthly treatment cycles over 12 weeks. - XytriX is given on top of standard care, and participants stay on their existing ALS medicines. - The primary endpoint is safety and tolerability, with safety follow-up through 12 months and surveillance through 24 months. - The secondary endpoint is a first look at efficacy, measured by change in ALS Functional Rating Scale–Revised decline after treatment. - Independent raters blinded to treatment arm will score ALSFRS-R changes. - The study has no placebo arm. - Each participant’s decline before treatment, during a 12-week observation period, will be compared with the same person’s post-treatment decline and with a matched comparator from the PRO-ACT database. - Each arm starts with one sentinel participant who is observed through a full cycle before others are dosed. - The intravenous arms will not open until the independent safety board overseeing the CTE study reviews its first intravenous cohort and clears the same dose. - The intranasal arm is a first for XytriX and uses small drops placed on the lining of the nose over about 30 to 45 minutes. - The study starts intranasal dosing at a lower dose before moving to the intended dose. - Intranasal dosing begins only after the delivery device and supporting nonclinical data have been submitted to the FDA. - TriCelX says the intranasal route is meant to bypass the blood-brain barrier through olfactory and trigeminal nerve pathways.

Between the lines: - TriCelX is building a single platform story around inflammation in the brain and spinal cord, linking CTE, ALS and knee osteoarthritis to one manufacturing process and one cell product. - The company is also tying the ALS program to its CTE work operationally, not just scientifically, by gating the ALS intravenous arms on safety review from the CTE study. - TriCelX’s thesis is that ALS progression may be influenced by the inflamed environment around motor neurons, not only the neurons themselves. - That remains a company model, not a proven clinical conclusion. - The release also cites higher ALS rates among former NFL players and military veterans, reinforcing the company’s focus on neurologic injury populations.

What’s next: - TriCelX will enroll the first sentinel participant in each arm and then expand dosing after safety review. - The company will collect 12-month safety data and continue safety surveillance out to 24 months. - Early efficacy signals will come from ALSFRS-R decline comparisons after treatment. - Intranasal dosing will begin after FDA review of the delivery device and nonclinical package. - TriCelX continues clinical development of XytriX in knee osteoarthritis and chronic traumatic encephalopathy.

The bottom line: - FDA clearance gives TriCelX a path to test XytriX in ALS using both infusion and a new needle-free nasal route, while the company tries to prove one cell platform can address multiple inflammation-linked diseases. - XytriX remains investigational and is not FDA approved.